1<!DOCTYPE html> 2<html lang="en"> 3<head> 4 5 6<title>The Share - Curasight</title> 7<meta property="og:title" content="The Share - Curasight" /> 8<meta name="twitter:title" content="The Share - Curasight" /> 9<link rel="canonical" href="https://www.curasight.com/investor/the-share/"> 10<meta charset="utf-8" /> 11<meta http-equiv="X-UA-Compatible" content="IE=edge" /> 12<meta name="viewport" content="width=device-width, initial-scale=1.0" /> 13<meta property="og:url" content="https://www.curasight.com/investor/the-share/" /> 14<meta name="twitter:url" content="https://www.curasight.com/investor/the-share/" /> 15<meta property="og:type" content="website"/> 16 17<meta name="Description" content="" /> 18<meta property="og:description" content="" /> 19<meta name="twitter:description" content="" /> 20<meta name="twitter:card" content="summary"> 21 22 23<style id="_cssgrid">#_44-2{grid-area:1/1/21/25;}@media(max-width: 768px) {._section-container[data-id^="44-"] ._grid { display: block; }} 24#_74-1{grid-area:11/1/24/25;}#_74-2{grid-area:1/1/11/25;}#_74-3{grid-area:1/1/70/25;}#_74-4{grid-area:1/1/15/25;}#_74-5{grid-area:1/1/41/25;}#_74-6{grid-area:1/1/10/25;}@media(max-width: 768px) {._section-container[data-id^="74-"] ._grid { display: block; }} 25#_11-1{grid-area:15/1/41/17;}#_11-3{grid-area:1/1/12/25;}#_11-4{grid-area:1/17/38/25;}#_11-5{grid-area:1/1/15/13;}@media(max-width: 768px){#_11-1{grid-area:14/1/24/13;}#_11-3{grid-area:1/1/12/25;}#_11-4{grid-area:1/13/29/25;}#_11-5{grid-area:1/1/14/13;}}@media(max-width: 667px){#_11-1{grid-area:14/1/24/25;}#_11-3{grid-area:1/1/6/25;}#_11-4{grid-area:24/1/52/25;}#_11-5{grid-area:1/1/14/25;}} 26</style> 27<style id="_iegrid">#_44-2{-ms-grid-row:1;-ms-grid-column:1;-ms-grid-row-span:20;-ms-grid-column-span:24;}#_74-1{-ms-grid-row:11;-ms-grid-column:1;-ms-grid-row-span:13;-ms-grid-column-span:24;}#_74-2{-ms-grid-row:1;-ms-grid-column:1;-ms-grid-row-span:10;-ms-grid-column-span:24;}#_74-3{-ms-grid-row:1;-ms-grid-column:1;-ms-grid-row-span:69;-ms-grid-column-span:24;}#_74-4{-ms-grid-row:1;-ms-grid-column:1;-ms-grid-row-span:14;-ms-grid-column-span:24;}#_74-5{-ms-grid-row:1;-ms-grid-column:1;-ms-grid-row-span:40;-ms-grid-column-span:24;}#_74-6{-ms-grid-row:1;-ms-grid-column:1;-ms-grid-row-span:9;-ms-grid-column-span:24;}#_11-1{-ms-grid-row:15;-ms-grid-column:1;-ms-grid-row-span:26;-ms-grid-column-span:16;}#_11-3{-ms-grid-row:1;-ms-grid-column:1;-ms-grid-row-span:11;-ms-grid-column-span:24;}#_11-4{-ms-grid-row:1;-ms-grid-column:17;-ms-grid-row-span:37;-ms-grid-column-span:8;}#_11-5{-ms-grid-row:1;-ms-grid-column:1;-ms-grid-row-span:14;-ms-grid-column-span:12;}@media(max-width: 768px){#_11-1{-ms-grid-row:14;-ms-grid-column:1;-ms-grid-row-span:10;-ms-grid-column-span:12;}#_11-3{-ms-grid-row:1;-ms-grid-column:1;-ms-grid-row-span:11;-ms-grid-column-span:24;}#_11-4{-ms-grid-row:1;-ms-grid-column:13;-ms-grid-row-span:28;-ms-grid-column-span:12;}#_11-5{-ms-grid-row:1;-ms-grid-column:1;-ms-grid-row-span:13;-ms-grid-column-span:12;}}@media(max-width: 667px){#_11-1{-ms-grid-row:14;-ms-grid-column:1;-ms-grid-row-span:10;-ms-grid-column-span:24;}#_11-3{-ms-grid-row:1;-ms-grid-column:1;-ms-grid-row-span:5;-ms-grid-column-span:24;}#_11-4{-ms-grid-row:24;-ms-grid-column:1;-ms-grid-row-span:28;-ms-grid-column-span:24;}#_11-5{-ms-grid-row:1;-ms-grid-column:1;-ms-grid-row-span:13;-ms-grid-column-span:24;}}</style> 28 29 30<link rel="stylesheet" href="/main.css?1774614085395" type="text/css"> 31 32 33 34<link rel="apple-touch-icon" sizes="180x180" href="/favicons/apple-touch-icon.png"> 35<link rel="icon" type="image/png" sizes="32x32" href="/favicons/favicon-32x32.png"> 36<link rel="icon" type="image/png" sizes="16x16" href="/favicons/favicon-16x16.png"> 37<link rel="manifest" href="/favicons/site.webmanifest"> 38<link rel="mask-icon" href="/favicons/safari-pinned-tab.svg" color="#446084"> 39<link rel="shortcut icon" href="/favicons/favicon.ico"> 40<meta name="msapplication-TileColor" content="#ffffff"> 41<meta name="msapplication-config" content="/favicons/browserconfig.xml"> 42<meta name="theme-color" content="#ffffff"> 43 44 45 46 47 48 49 50 51 52</head> 53<body class="no-js live page74 sticky-all subnav-type-hover subnav-width-auto nav-thirdlevel-hidden nav-swipe-right nav-toggle-right"> 54 <div id="top"></div> 55 <svg style="display: none;"> 56 <symbol id="svg-Close" viewBox="0 0 44 44"><path d="M38.824 0L44 5.178 5.176 44 0 38.825 38.824 0z" fill="currentColor"></path><path d="M5.176 0L44 38.825 38.824 44 0 5.178 5.176 0z" fill="currentColor"></path></symbol><symbol id="svg-Nav-hide" viewBox="0 0 26 26"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 1024 1024">
56<path fill="currentColor" d="M0 789q0 5 2 10t5 8q8 8 18.5 8t18.5-8l442-442 443 442q8 8 18.5 8t17.5-8q8-7 8-17.5t-8-18.5L504 310q-7-7-17.5-7t-18.5 7L7 771q-3 4-5 8.5T0 789z"/></svg></symbol><symbol id="svg-Nav-show" viewBox="0 0 26 26"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 1024 1024"><path fill="currentColor" d="M0 329q0-5 2-10t5-9q8-7 18.5-7t18.5 7l442 443 443-443q8-7 18.5-7t17.5 7q8 8 8 18.5t-8 18.5L504 807q-7 8-17.5 8t-18.5-8L7 347q-3-4-5-9t-2-10v1z"/></svg></symbol><symbol id="svg-LinkedIn" viewBox="0 0 1792 1792"><path d="M477 625v991H147V625h330zm21-306q1 73-50.5 122T312 490h-2q-82 0-132-49t-50-122q0-74 51.5-122.5T314 148t133 48.5T498 319zm1166 729v568h-329v-530q0-105-40.5-164.5T1168 862q-63 0-105.5 34.5T999 982q-11 30-11 81v553H659q2-399 2-647t-1-296l-1-48h329v144h-2q20-32 41-56t56.5-52 87-43.5T1285 602q171 0 275 113.5t104 332.5z" fill="currentColor"></path></symbol><symbol id="svg-YouTube-play" viewBox="0 0 147 147"><path d="M73.5 147C32.907 147 0 114.093 0 73.5S32.907 0 73.5 0 147 32.907 147 73.5 114.093 147 73.5 147zm29.01-73.29L55.59 50.327a2 2 0 0 0-2.892 1.79v46.767a2 2 0 0 0 2.892 1.79l46.92-23.384a2 2 0 0 0 0-3.58z" fill="currentColor" fill-rule="evenodd"></path></symbol><symbol id="svg-Search" viewBox="0 0 1792 1792"><path fill="currentColor" d="M1216 832q0-185-131.5-316.5t-316.5-131.5-316.5 131.5-131.5 316.5 131.5 316.5 316.5 131.5 316.5-131.5 131.5-316.5zm512 832q0 52-38 90t-90 38q-54 0-90-38l-343-342q-179 124-399 124-143 0-273.5-55.5t-225-150-150-225-55.5-273.5 55.5-273.5 150-225 225-150 273.5-55.5 273.5 55.5 225 150 150 225 55.5 273.5q0 220-124 399l343 343q37 37 37 90z"/></symbol><symbol id="svg-E-mail" viewBox="0 0 1792 1792"><path d="M1792 710v794q0 66-47 113t-113 47H160q-66 0-113-47T0 1504V710q44 49 101 87 362 246 497 345 57 42 92.5 65.5t94.5 48 110 24.5h2q51 0 110-24.5t94.5-48 92.5-65.5q170-123 498-345 57-39 100-87zm0-294q0 79-49 151t-122 123q-376 261-468 325-10 7-42.5 30.5t-54 38-52 32.5-57.5 27-50 9h-2q-23 0-50-9t-57.5-27-52-32.5-54-38T639 1015q-91-64-262-182.5T172 690q-62-42-117-115.5T0 438q0-78 41.5-130T160 256h1472q65 0 112.5 47t47.5 113z" fill="currentColor"></path></symbol> 57</svg> 58 59 60 61 62<a class="_skiplink" id="_skiptocontent" href="#_main" accesskey="s"><span>Skip to main content</span></a><a class="_skiplink" id="_skiptonav" href="#_mainnav"><span>Skip to navigation</span></a><a class="_skiplink" id="_skiptosearch" href="#"><span>Skip to search</span></a> 63 64<header> 65 <div id="_mobile-header"><a class="_logotype" href="/"><img src="/files/images/curasight-site-logo.png" alt="Curasight"></a><button role="button" id="_toggle-nav" aria-expanded="false" aria-controls="_mobile-menu"> 66 <span> 67 <span class="show">Menu</span> 68 <span class="hide">Close</span> 69 </span> 70 </button></div> 71 <div id="_mobile-menu" class="_mobile-menu"> 72 <div class="_mobile-menu-row _row-0"> 73 <div class="_searchform desktop-lightbox mob-regular"> 74 <form action="/search/"> 75 <input aria-label="Search" class="_searchbox" placeholder="Search" name="q" value="" autocomplete="off" /><button aria-label="Submit search"><svg role="img" width="1792" height="1792" viewBox="0 0 1792 1792"> 76 <use xlink:href="#svg-Search"></use> 77 </svg></button> 78 <div class="_instantsearch" data-nohits="No results found"></div> 79 </form> 80 81 <button class="_toggleSearch" aria-hidden="true"><svg role="img" width="1792" height="1792" viewBox="0 0 1792 1792"> 82 <use xlink:href="#svg-Search"></use> 83 </svg></button> 84 85 </div> 86</div> 87 <div id="_desktop-header"><div class="_cell-0-0"></div><div class="_cell-0-1"><a href="/investor/the-share/" id="_ticker"><div class="ticker"> 88 <div class="_ticker-text"> 89 <strong><span class="_ticker-price"> </span> DKK</strong> 90 <span class="_ticker-changePerc"> </span>% 91 | <span data-tickerformat="D MMM, YYYY" data-when="QuoteTime"></span> 92 </div> 93</div> 94</a><!-- --></div><div class="_cell-0-2"></div><div class="_cell-1-0"></div><div class="_cell-1-1"><a class="_logotype" href="/"><img src="/files/images/curasight-site-logo.png" alt="Curasight"></a><nav id="_mainnav" aria-label="Main navigation"> 95<ul id="_menu1" class="level1" data-togglelabel="Toggle navigation"><li><a href="/about-us/">About Us</a><ul id="_menu12" class="level2" aria-hidden="true"><li><a href="/about-us/our-motivation/">Our Motivation</a></li><li><a href="/about-us/management-team/">Management Team</a></li><li><a href="/about-us/board-of-directors/">Board of Directors</a></li><li><a href="/about-us/history/">History</a></li></ul></li><li><a href="/upar-the-target/">uPAR â the Target</a><ul id="_menu16" class="level2" aria-hidden="true"><li><a href="/upar-the-target/upar-theranostics/">uPAR Theranostics</a></li><li><a href="/upar-the-target/utrace/">uTRACE®</a></li><li><a href="/upar-the-target/utreat/">uTREAT®</a></li><li><a href="/upar-the-target/disease-areas/">Disease Areas</a></li><li><a href="/upar-the-target/publications/">Publications</a></li></ul></li><li><a href="/pipeline/">Pipeline</a></li><li><a href="/news/">News and Media</a><ul id="_menu27" class="level2" aria-hidden="true"><li><a href="/news/press-releases/">Press releases</a></li><li><a href="/news/presentations/">Presentations</a></li><li><a href="/news/subscribe/">Subscribe</a></li><li><a href="/news/frequently-asked-questions/">FAQ</a></li></ul></li><li class="expanded"><a href="/investor/">Investor</a><ul id="_menu22" class="level2" aria-hidden="true"><li><a href="/investor/curasight-as-an-investment/">Curasight as an investment</a></li><li><a href="/investor/reports/">Financial reports</a></li><li class="expanded selected"><a href="/investor/the-share/">The Share</a></li><li><a href="/investor/general-meetings/">General meetings</a></li><li><a href="/investor/calendar/">Calendar</a></li><li><a href="/investor/events/">Events</a></li><li><a href="/investor/corporate-governance/">Corporate Governance</a></li><li><a href="/investor/analyst-coverage/">Analysts</a></li><li><a href="/investor/archive-financing/">Archive financing</a></li></ul></li><li><a href="/contact/">Contact</a></li></ul></nav>
96 <div class="_searchform desktop-lightbox mob-regular"> 97 <form action="/search/"> 98 <input aria-label="Search" class="_searchbox" placeholder="Search" name="q" value="" autocomplete="off" /><button aria-label="Submit search"><svg role="img" width="1792" height="1792" viewBox="0 0 1792 1792"> 99 <use xlink:href="#svg-Search"></use> 100 </svg></button> 101 <div class="_instantsearch" data-nohits="No results found"></div> 102 </form> 103 104 <button class="_toggleSearch" aria-hidden="true"><svg role="img" width="1792" height="1792" viewBox="0 0 1792 1792"> 105 <use xlink:href="#svg-Search"></use> 106 </svg></button> 107 108 </div> 109</div><div class="_cell-1-2"></div></div> 110 111 </div> 112</header> 113 114<nav class="breadcrumb" aria-label="Breadcrumb"><ul><li><a href="/">Home</a></li><li><a href="/investor/">Investor</a></li><li><p>The Share</p></li></ul></nav> 115 116 <div id="_middleregion"><div id="_leftregion"> 117 <div data-id="44-1" class="_section-container"> 118 119 <div class="_section"> 120 <div class="_grid"> 121 122 <div id="_44-2" class="_block"> 123 124 125 <div class="_block-content"> 126 127<nav id="subnav" aria-label="Section"> 128<h2><a href="/investor/">Investor</a></h2><ul><li><a href="/investor/curasight-as-an-investment/">Curasight as an investment</a></li><li><a href="/investor/reports/">Financial reports</a></li><li class="expanded"><a href="/investor/the-share/" class="selected">The Share</a></li><li><a href="/investor/general-meetings/">General meetings</a></li><li><a href="/investor/calendar/">Calendar</a></li><li><a href="/investor/events/">Events</a></li><li><a href="/investor/corporate-governance/">Corporate Governance</a></li><li><a href="/investor/analyst-coverage/">Analysts</a></li><li><a href="/investor/archive-financing/">Archive financing</a></li></ul> 129</nav> 130 </div> 131 132 133 </div> 134 135 </div> 136 </div> 137 138 </div> 139 </div><main id="_main"> 140 <div data-id="74-1" class="_section-container"> 141 142 <div class="_section"> 143 <div class="_grid"> 144 145 <div id="_74-2" class="_block"> 146 147 148 <div class="_block-content"> 149 <h1>The Share</h1> 150 </div> 151 152 153 </div> 154 155 <div id="_74-1" class="_block"> 156 157 158 <div class="_block-content"> 159 <table class="share-summary share-summary--top"> 160 <thead> 161 <tr> 162 <th><span data-tickerformat="dddd, D MMMM YYYY, HH:mm" data-when="QuoteTime"></span></th> 163 <th>Current</th> 164 <th>Change</th> 165 <th>Change (%)</th> 166 </tr> 167 </thead> 168 <tbody> 169 <tr> 170 <td>CURAS (Spotlight, Copenhagen) DKK/share</td> 171 <td><span class="_ticker-price"></span></td> 172 <td><span class="_ticker-change"></span></td> 173 <td><span class="_ticker-changePerc"></span></td> 174 </tr> 175 </tbody> 176</table> 177 178<table class="share-summary"> 179 <thead> 180 <tr> 181 <th>Bid</th> 182 <th>Ask</th> 183 <th>High</th> 184 <th>Low</th> 185 <th>Volume</th> 186 </tr> 187 </thead> 188 <tbody> 189 <tr> 190 <td><span class="_ticker-bid"></span></td> 191 <td><span class="_ticker-ask"></span></td> 192 <td><span class="_ticker-high"></span></td> 193 <td><span class="_ticker-low"></span></td> 194 <td><span class="_ticker-volume"></span></td> 195 </tr> 196 </tbody> 197</table> 198 199 </div> 200 201 202 </div> 203 204 </div> 205 </div> 206 207 </div> 208 209 <div data-id="74-2" class="_section-container"> 210 211 <div class="_section"> 212 <div class="_grid"> 213 214 <div id="_74-3" class="_block"> 215 216 217 <div class="_block-content"> 218 219<figure id="_sharegraph" class="_chart _sharegraph" data-color="#446084" data-symbol="CURAS" data-lang="en" data-divisor="1000" data-total-return-label=""> 220 <div class="_shortcuts"> 221 222 <button data-type="1d" data-default="false">1D</button> 223 224 <button data-type="5d" data-default="false">5D</button> 225 226 <button data-type="1m" data-default="false">1M</button> 227 228 <button data-type="6m" data-default="false">6M</button> 229 230 <button data-type="1y" data-default="false">1Y</button> 231 232 <button data-type="5y" data-default="false">5Y</button> 233 234 </div> 235 236 <div class="_peers"> 237 <div></div> 238 239 <label> 240 <input type="checkbox" data-color="#cccccc" data-symbol
240="SPTIDX"> 241 <span>Spotlight Index (SEK)</span> 242 </label> 243 244 </div> 245 246 <div class="_chart-container"> 247 <div class="_y-axis right"></div> 248 <div class="_y-axis right bottom"></div> 249 250 <div class="_gridlines"></div> 251 <div class="_chart-area _margin"> 252 <div class="_hoverline legend"></div> 253 </div> 254 <div class="_newsitems _margin"></div> 255 <div class="_volumeLabel">Volume, thousands</div> 256 <div class="_volume _margin"></div> 257 <div class="_timeline _margin"> 258 <div class="_minor"></div> 259 <div class="_major"></div> 260 </div> 261 <div class="_navchart"> 262 <div class="_leftcover _cover"></div> 263 <div class="_rightcover _cover"></div> 264 <div class="_handle _left"></div> 265 <div class="_navcover"></div> 266 <div class="_handle _right"></div> 267 <div class="_years"></div> 268 <svg xmlns="http://www.w3.org/2000/svg"></svg> 269 </div> 270 </div> 271 <div class="_newsjson">[{"d":"2026-01-05","n":"Curasight to hold Meetings in San Francisco During J.P. Morgan Healthcare Conference Week","u":"/news/press-releases/2026/curasight-to-hold-meetings-in-san-francisco-during-j-p-morgan-healthcare-conference-week/"},{"d":"2026-01-12","n":"Curasight Announces Encouraging Preliminary Data from Phase 1 Trial Evaluating First-in-Class Radiopharmaceutical uTREAT[®] in High-Grade Gliomas","u":"/news/press-releases/2026/curasight-announces-encouraging-preliminary-data-from-phase-1-trial-evaluating-first-in-class-radiopharmaceutical-utreat-in-high-grade-gliomas/"},{"d":"2026-02-09","n":"Major Shareholding Notification","u":"/news/press-releases/2026/major-shareholding-notification/"},{"d":"2026-02-17","n":"Curasight to present at TD Cowen's 46th Annual Health Care Conference in Boston","u":"/news/press-releases/2026/curasight-to-present-at-td-cowens-46th-annual-health-care-conference-in-boston/"},{"d":"2026-02-26","n":"Year-end report Q4 2025","u":"/news/press-releases/2026/year-end-report-q4-2025/"},{"d":"2026-02-26","n":"Annual Report 2025","u":"/news/press-releases/2026/annual-report-2025/"},{"d":"2026-03-06","n":"Curasight reduces convertible debt as Fenja Capital converts and enters into a block trade","u":"/news/press-releases/2026/curasight-reduces-convertible-debt-as-fenja-capital-converts-and-enters-into-a-block-trade/"},{"d":"2026-03-10","n":"Notice of Annual General Meeting 2026","u":"/news/press-releases/2026/notice-of-annual-general-meeting-2026/"},{"d":"2026-03-25","n":"Resolutions of the Annual General Meeting 2026 of Curasight A/S","u":"/news/press-releases/2026/resolutions-of-the-annual-general-meeting-2026-of-curasight-as/"},{"d":"2026-04-26","n":"Major Shareholding Notification - share transfer and ownership restructuring â related party transaction","u":"/news/press-releases/2026/major-shareholding-notification--share-transfer-and-ownership-restructuring-related-party-transaction/"},{"d":"2026-05-28","n":"Interim report Q1 2026","u":"/news/press-releases/2026/interim-report-q1-2026/"},{"d":"2026-06-08","n":"Curasight Announces Preliminary Readout from its Phase 1 Clinical Trial with uTREAT[®] in Aggressive Brain Cancer (Glioblastoma)","u":"/news/press-releases/2026/curasight-announces-preliminary-readout-from-its-phase-1-clinical-trial-with-utreat-in-aggressive-brain-cancer-glioblastoma/"},{"d":"2026-06-22","n":"Curasight A/S announces its intention to carry out a directed issue of shares","u":"/news/press-releases/2026/curasight-as-announces-its-intention-to-carry-out-a-directed-issue-of-shares/"},{"d":"2026-06-22","n":"Curasight A/S has successfully completed a directed issue of shares of approximately DKK 20 million","u":"/news/press-releases/2026/curasight-as-has-successfully-completed-a-directed-issue-of-shares-of-approximately-dkk-20-million/"},{"d":"2026-07-27","n":"Curasight Announces protocol update for the Phase I uTREAT trial in Aggressive Brain Cancer (Glioblastoma)","u":"/news/press-releases/2026/curasight-announces-protocol-update-for-the-phase-i-utreat-trial-in-aggressive-brain-cancer-glioblastoma/"},{"d":"2026-08-27","n":"Curasight publishes Interim Report Q2 2026","u":"/news/press-releases/2026/curasight-publishes-interim-report-q2-2026/"},{"d":"2026-09-14","n":"Major Shareholding Notification - ownership restructuring â related party transaction","u":"/news/press-releases/2026/major-shareholding-notification--ownership-restructuring-related-party-transaction/"},{"d":"2025-09-03","n":"Transaction with shares in Curasight A/S made by managerial employee","u":"/news/press-releases/2025/transaction-with-shares-in-curasight-as-made-by-managerial-employee/"},{"d":"2025-10-01","n":"Curasight announces broadening and extension of patent protection for uTRACE®","u":"/news/press-releases/2025/curasight-announces-broadening-and-extension-of-patent-protection-for-utrace/"},{"d":"2025-10-29","n":"Curasight advances Phase 2 uTRACE prostate cancer trial with all European clinical sites in Part 2 now recruiting","u":"/news/press-releases/2025/curasight-advances-phase-2-utrace-prostate-cancer-trial-with-all-european-clinical-sites-in-part-2-now-recruiting/"},{"d":"2025-11-13","n":"Curasight to present at Dansk Aktionærforening InvestorDagen","u":"/news/press-releases/2025/curasight-to-present-at-dansk-aktionaerforening-investordagen/"},{"d":"2025-11-26","n":"Curasightâs uTREAT® Phase 1 Trial in Brain Cancer Now Open for Patient Enrollment","u":"/news/press-releases/2025/curasights-utreat-phase-1-trial-in-brain-cancer-now-open-for-patient-enrollment/"},{"d":"2025-11-27","n":"Interim report Q3 2025","u":"/news/press-releases/2025/interim-report-q3-2025/"},{"d":"2025-11-28","n":"Curasight to present at HC Andersen Capital","u":"/news/press-releases/2025/curasight-to-present-at-hc-andersen-capital-2025-11-28/"},{"d":"2025-12-12","n":"Curasight A/S announces its intention to carry out a directed issue of shares and enter into a
271new loan facility","u":"/news/press-releases/2025/curasight-as-announces-its-intention-to-carry-out-a-directed-issue-of-shares-and-enter-into-a-new-loan-facility/"},{"d":"2025-12-12","n":"Curasight A/S has successfully completed a directed issue of shares of approximately DKK 16.4 million and has entered into a new loan facility","u":"/news/press-releases/2025/curasight-as-has-successfully-completed-a-directed-issue-of-shares-of-approximately-dkk-16-4-million-and-has-entered-into-a-new-loan-facility/"},{"d":"2025-12-14","n":"Notice of Extraordinary General Meeting","u":"/news/press-releases/2025/notice-of-extraordinary-general-meeting/"},{"d":"2025-12-18","n":"Curasight Announces Successful Dosing of First Patient in Phase 1 trial with uTREAT[®] in Brain Cancer","u":"/news/press-releases/2025/curasight-announces-successful-dosing-of-first-patient-in-phase-1-trial-with-utreat-in-brain-cancer/"},{"d":"2025-12-29","n":"Resolutions of the Extraordinary General Meeting December 2025","u":"/news/press-releases/2025/resolutions-of-the-extraordinary-general-meeting-december-2025/"},{"d":"2025-12-29","n":"Curasight A/S resolves to issue a convertible loan note","u":"/news/press-releases/2025/curasight-as-resolves-to-issue-a-convertible-loan-note/"},{"d":"2025-02-05","n":"Curasight announces an updated financial calendar 2025","u":"/news/press-releases/2025/curasight-announces-an-updated-financial-calendar-2025/"},{"d":"2025-02-27","n":"Year-end report Q4 2024","u":"/news/press-releases/2025/year-end-report-q4-2024/"},{"d":"2025-03-26","n":"Curasight announces new date of the Annual General Meeting and an updated financial calendar 2025","u":"/news/press-releases/2025/curasight-announces-new-date-of-the-annual-general-meeting-and-an-updated-financial-calendar-2025/"},{"d":"2025-04-04","n":"Curasight A/S resolves on its intention to carry out a rights issue of shares of approximately DKK 100 million","u":"/news/press-releases/2025/curasight-as-resolves-on-its-intention-to-carry-out-a-rights-issue-of-shares-of-approximately-dkk-100-million/"},{"d":"2025-04-08","n":"Notice of Extraordinary General Meeting of Curasight A/S","u":"/news/press-releases/2025/notice-of-extraordinary-general-meeting-of-curasight-as/"},{"d":"2025-04-23","n":"Resolutions of the Extraordinary General Meeting of Curasight A/S on 23 April 2025","u":"/news/press-releases/2025/resolutions-of-the-extraordinary-general-meeting-of-curasight-as-on-23-april-2025/"},{"d":"2025-04-24","n":"CURASIGHT A/S ANNOUNCES FINAL TERMS OF RIGHTS ISSUE","u":"/news/press-releases/2025/curasight-as-announces-final-terms-of-rights-issue/"},{"d":"2025-04-25","n":"Interim report Q1 2025","u":"/news/press-releases/2025/interim-report-q1-2025/"},{"d":"2025-04-25","n":"Annual Report for the fiscal year 2024","u":"/news/press-releases/2025/annual-report-for-the-fiscal-year-2024/"},{"d":"2025-04-29","n":"Curasight A/S publishes disclosure document regarding rights issue","u":"/news/press-releases/2025/curasight-as-publishes-disclosure-document-regarding-rights-issue/"},{"d":"2025-04-30","n":"Curasight to present at HC Andersen Capital","u":"/news/press-releases/2025/curasight-to-present-at-hc-andersen-capital/"},{"d":"2025-05-02","n":"THE SUBSCRIPTION PERIOD IN CURASIGHTâS RIGHTS ISSUE OF SHARES BEGINS TODAY","u":"/news/press-releases/2025/the-subscription-period-in-curasights-rights-issue-of-shares-begins-today/"},{"d":"2025-05-07","n":"Curasight A/S selects CRO to run Phase 1 trial with uTREAT[®] in brain cancer","u":"/news/press-releases/2025/curasight-as-selects-cro-to-run-phase-1-trial-with-utreat-in-brain-cancer/"},{"d":"2025-05-13","n":"Last day of the subscription period in Curasightâs rights issue of shares","u":"/news/press-releases/2025/last-day-of-the-subscription-period-in-curasights-rights-issue-of-shares/"},{"d":"2025-05-13","n":"Notice of Annual General Meeting 2025","u":"/news/press-releases/2025/notice-of-annual-general-meeting-2025/"},{"d":"2025-05-15","n":"Subscription of new shares in the Right Issue 2025 exercised by Curasight management","u":"/news/press-releases/2025/subscription-of-new-shares-in-the-right-issue-2025-exercised-by-curasight-management/"},{"d":"2025-05-21","n":"Curasight announces outcome in rights issue","u":"/news/press-releases/2025/curasight-announces-outcome-in-rights-issue/"},{"d":"2025-05-28","n":"Resolutions of the Annual General Meeting 2025 of Curasight A/S","u":"/news/press-releases/2025/resolutions-of-the-annual-general-meeting-2025-of-curasight-as/"},{"d":"2025-05-28","n":"Completed registration of rights issue","u":"/news/press-releases/2025/completed-registration-of-rights-issue/"},{"d":"2025-06-02","n":"Curasight carries out a directed issue of shares to guarantors in connection with the completed rights issue","u":"/news/press-releases/2025/curasight-carries-out-a-directed-issue-of-shares-to-guarantors-in-connection-with-the-completed-rights-issue/"},{"d":"2025-06-03","n":"The exercise period commences for warrants of series TO3 on 4 June 2025","u":"/news/press-releases/2025/the-exercise-period-commences-for-warrants-of-series-to3-on-4-june-2025/"},{"d":"2025-06-18","n":"Curasight A/S submits Clinical Trial Application for Phase 1 trial with uTREAT[®] in brain cancer patients","u":"/news/press-releases/2025/curasight-as-submits-clinical-trial-application-for-phase-1-trial-with-utreat-in-brain-cancer-patients/"},{"d":"2025-06-23","n":"Curasight A/S announces outcome of T03 warrant exercise","u":"/news/press-releases/2025/curasight-as-announces-outcome-of-t03-warrant-exercise/"},{"d":"2025-08-26","n":"Curasight announces acceptance of clinical trial application (CTA) for phase 1 trial with uTREAT[®] in brain cancer patients","u":"/news/press-releases/2025/curasight-announces-acceptance-of-clinical-trial-application-cta-for-phase-1-trial-with-utreat-in-brain-cancer-patients/"},{"d":"2025-08-28","n":"Half-year report Q2 2025","u":"/news/press-releases/2025/half-year-report-q2-2025/"},{"d":"2024-01-22","n":"Curasight A/S Achieves First Milestone under collaboration with Curium Inc.","u":"/news/press-releases/2024/curasight-as-achieves-first-milestone-under-collaboration-with-curium-inc/"},{"d":"2024-02-13","n":"Curasight announces acceleration of therapeutic strategy to strengthen position as a radiopharmaceutical theranostic company","u":"/news/press-releases/2024/curasight-announces-acceleration-of-therapeutic-strategy-to-strengthen-position-as-a-radiopharmaceutical-theranostic-company/"},{"d":"2024-02-13","n":"Curasight resolves on a rights issue of up to DKK 51.2 million to accelerate its therapeutic strategy","u":"/investor/archive-financing/rights-issue-2024/curasight-resolves-on-a-rights-issue-of-up-to-dkk-51-2-million-to-accelerate-its-therapeutic-strategy/"},{"d":"2024-02-22","n":"Year-end report October â December 2023","u":"/news/press-releases/2024/year-end-report-october-december-2023/"},{"d":"2024-02-22","n":"Annual Report for the fiscal year 2023","u":"/news/press-releases/2024/annual-report-for-the-fiscal-year-2023/"},{"d":"2024-02-22","n":"Curasight publishes information memorandum in connection with forthcoming rights issue","u":"/investor/archive-financing/rights-issue-2024/curasight-publishes-information-memorandum-in-connection-with-forthcoming-rights-issue/"},{"d":"2024-02-23","n":"The subscription period in Curasightâs rights issue begins today","u":"/investor/archive-financing/rights-issue-2024/the-subscription-period-in-curasights-rights-issue-begins-today/"},{"d":"2024-03-06","n":"Notice of Annual General Meeting 2024","u":"/news/press-releases/2024/notice-
271of-annual-general-meeting-2024/"},{"d":"2024-03-11","n":"Curasight not to proceed with rights issue; evaluating alternative financing opportunities","u":"/news/press-releases/2024/curasight-not-to-proceed-with-rights-issue-evaluating-alternative-financing-opportunities/"},{"d":"2024-03-21","n":"Resolutions of the Annual General Meeting 2024 of Curasight A/S","u":"/news/press-releases/2024/resolutions-of-the-annual-general-meeting-2024-of-curasight-as/"},{"d":"2024-04-12","n":"Curasight announces change in the Board of Directors","u":"/news/press-releases/2024/curasight-announces-change-in-the-board-of-directors/"},{"d":"2024-04-16","n":"Curasight announces approval of clinical trial application (CTA) for phase 2 trial with uTRACE[®] in prostate cancer patients","u":"/news/press-releases/2024/curasight-announces-approval-of-clinical-trial-application-cta-for-phase-2-trial-with-utrace-in-prostate-cancer-patients/"},{"d":"2024-05-23","n":"Interim report Q1 2024","u":"/news/press-releases/2024/interim-report-q1-2024/"},{"d":"2024-06-12","n":"Curasight Announces Enrollment of First Patient in Phase 2 trial with uTRACE[®] in Prostate Cancer","u":"/news/press-releases/2024/curasight-announces-enrollment-of-first-patient-in-phase-2-trial-with-utrace-in-prostate-cancer/"},{"d":"2024-06-14","n":"Curasight A/S resolves on directed issues and a loan facility","u":"/news/press-releases/2024/curasight-as-resolves-on-directed-issues-and-a-loan-facility/"},{"d":"2024-06-17","n":"Notice of Extraordinary General Meeting","u":"/news/press-releases/2024/notice-of-extraordinary-general-meeting/"},{"d":"2024-06-22","n":"Curasight to present at HC Andersen Capital","u":"/news/press-releases/2024/curasight-to-present-at-hc-andersen-capital/"},{"d":"2024-07-01","n":"Directed issues registered at the Danish Business Authority","u":"/news/press-releases/2024/directed-issues-registered-at-the-danish-business-authority/"},{"d":"2024-07-02","n":"Resolutions of the Extraordinary General Meeting of Curasight A/S on 2 July 2024","u":"/news/press-releases/2024/resolutions-of-the-extraordinary-general-meeting-of-curasight-as-on-2-july-2024/"},{"d":"2024-07-30","n":"Curasight issues warrants as part of long-term incentive program","u":"/news/press-releases/2024/curasight-issues-warrants-as-part-of-long-term-incentive-program/"},{"d":"2024-08-22","n":"Interim report Q2 2024","u":"/news/press-releases/2024/interim-report-q2-2024/"},{"d":"2024-09-04","n":"The Board of Directors resolves on a directed issue of units and preferential rights issue of units","u":"/news/press-releases/2024/the-board-of-directors-resolves-on-a-directed-issue-of-units-and-preferential-rights-issue-of-units/"},{"d":"2024-09-12","n":"Curasight A/S publishes prospectus due to upcoming rights issue","u":"/news/press-releases/2024/curasight-as-publishes-prospectus-due-to-upcoming-rights-issue/"},{"d":"2024-09-16","n":"Commencement of subscription period in Curasightâs preferential rights issue","u":"/news/press-releases/2024/commencement-of-subscription-period-in-curasights-preferential-rights-issue/"},{"d":"2024-10-03","n":"Curasight A/S rights issue heavily oversubscribed","u":"/news/press-releases/2024/curasight-as-rights-issue-heavily-oversubscribed/"},{"d":"2024-10-11","n":"Curasight A/S announces last day of trading in BTU and first day of trading in warrant series TO2 and TO3","u":"/news/press-releases/2024/curasight-as-announces-last-day-of-trading-in-btu-and-first-day-of-trading-in-warrant-series-to2-and-to3/"},{"d":"2024-11-07","n":"Clinical phase II trial of uPAR-PET in brain cancer patients published; data supports development of uTREAT for brain cancer","u":"/news/press-releases/2024/clinical-phase-ii-trial-of-upar-pet-in-brain-cancer-patients-published-data-supports-development-of-utreat-for-brain-cancer/"},{"d":"2024-11-08","n":"Curasight to present at Dansk Aktionærforening InvestorDagen","u":"/news/press-releases/2024/curasight-to-present-at-dansk-aktionaerforening-investordagen/"},{"d":"2024-11-11","n":"Curasight announces brain cancer as first indication for uTREAT[®]: First patient to be dosed Q2 2025","u":"/news/press-releases/2024/curasight-announces-brain-cancer-as-first-indication-for-utreat-first-patient-to-be-dosed-q2-2025/"},{"d":"2024-11-13","n":"Curasight announces international patent application for uTREAT® to broaden IP protection","u":"/news/press-releases/2024/curasight-announces-international-patent-application-for-utreat-to-broaden-ip-protection/"},{"d":"2024-11-14","n":"Curasight to present at HC Andersen Capital, BioStock Life Science Summit 2024, and Ãkonomisk Ugebrev Investor Conference","u":"/news/press-releases/2024/curasight-to-present-at-hc-andersen-capital-biostock-life-science-summit-2024-and-okonomisk-ugebrev-investor-conference/"},{"d":"2024-11-20","n":"The exercise price for warrants of series TO2 has been set to DKK 11.50 per new share","u":"/news/press-releases/2024/the-exercise-price-for-warrants-of-series-to2-has-been-set-to-dkk-11-50-per-new-share/"},{"d":"2024-11-21","n":"Interim report Q3 2024","u":"/news/press-releases/2024/interim-report-q3-2024/"},{"d":"2024-11-21","n":"The exercise period for warrants of series TO2 commences today","u":"/news/press-releases/2024/the-exercise-period-for-warrants-of-series-to2-commences-today/"},{"d":"2024-11-22","n":"Curasight and Curium sign global radioisotope supply agreement for uTREAT[®]","u":"/news/press-releases/2024/curasight-and-curium-sign-global-radioisotope-supply-agreement-for-utreat/"},{"d":"2024-12-02","n":"The last day of trading in warrants of series TO2 is on the 3[rd] of December 2024","u":"/news/press-releases/2024/the-last-day-of-trading-in-warrants-of-series-to2-is-on-the-3rd-of-december-2024/"},{"d":"2024-12-02","n":"SEB maintain valuation range midpoint at DKK 54 per share","u":"/news/press-releases/2024/seb-maintain-valuation-range-midpoint-at-dkk-54-per-share/"},{"d":"2024-12-10","n":"Curasight A/S announces outcome of warrant exercise","u":"/news/press-releases/2024/curasight-as-announces-outcome-of-warrant-exercise/"},{"d":"2024-12-10","n":"Participation in warrant exercise by Curasight management","u":"/news/press-releases/2024/participation-in-warrant-exercise-by-curasight-management/"},{"d":"2023-01-16","n":"Curasight to present at Redeye Fight Cancer Seminar","u":"/news/press-releases/2023/curasight-to-present-at-redeye-fight-cancer-seminar/"},{"d":"2023-02-22","n":"Curasight to present at HC Andersen Capital","u":"/news/press-releases/2023/curasight-to-present-at-hc-andersen-capital/"},{"d":"2023-02-23","n":"Year-end report October - December 2022","u":"/news/press-releases/2023/year-end-report-october---december-2022/"},{"d":"2023-02-23","n":"Annual Report for the fiscal year 2022","u":"/news/press-releases/2023/annual-report-for-the-fiscal-year-2022/"},{"d":"2023-03-15","n":"Notice of Annual General Meeting 2023","u":"/news/press-releases/2023/notice-
271of-annual-general-meeting-2023/"},{"d":"2023-03-30","n":"Resolutions of the Annual General Meeting of Curasight A/S","u":"/news/press-releases/2023/resolutions-of-the-annual-general-meeting-of-curasight-as/"},{"d":"2023-05-01","n":"Curasight and Curium announce global partnership for uTRACE[®] in prostate cancer","u":"/news/press-releases/2023/curasight-and-curium-announce-global-partnership-for-utrace-in-prostate-cancer/"},{"d":"2023-05-25","n":"Interim report Q1 2023","u":"/news/press-releases/2023/interim-report-q1-2023/"},{"d":"2023-05-26","n":"Curasight to present at HC Andersen Capital and Ãkonomisk Ugebrev","u":"/news/press-releases/2023/curasight-to-present-at-hc-andersen-capital-and-okonomisk-ugebrev/"},{"d":"2023-06-07","n":"Curasight A/S reports positive preclinical results with uTREAT[®] in aggressive brain cancer (glioblastoma)","u":"/news/press-releases/2023/curasight-as-reports-positive-preclinical-results-with-utreat-in-aggressive-brain-cancer-glioblastoma/"},{"d":"2023-06-29","n":"Positive results in uPAR-PET/MR Phase II study in brain cancer","u":"/news/press-releases/2023/positive-results-in-upar-petmr-phase-ii-study-in-brain-cancer/"},{"d":"2023-08-24","n":"Interim Report January â June 2023","u":"/news/press-releases/2023/interim-report-january--june-2023/"},{"d":"2023-08-25","n":"Curasight to present at HC Andersen Capital and at HC Andersen Life Science seminar","u":"/news/press-releases/2023/curasight-to-present-at-hc-andersen-capital-and-at-hc-andersen-life-science-seminar/"},{"d":"2023-09-14","n":"Positive results from the Phase II study of uTRACE in brain cancer presented at the World Molecular Imaging Congress (WMIC) 2023 in Prague","u":"/news/press-releases/2023/positive-results-from-the-phase-ii-study-of-utrace-in-brain-cancer-presented-at-the-world-molecular-imaging-congress-wmic-2023-in-prague/"},{"d":"2023-10-18","n":"Curasight A/S reports positive preclinical results with uTREAT[®] in lung cancer (NSCLC)","u":"/news/press-releases/2023/curasight-as-reports-positive-preclinical-results-with-utreat-in-lung-cancer-nsclc/"},{"d":"2023-11-23","n":"Interim Report January â September 2023","u":"/news/press-releases/2023/interim-report-january--september-2023/"},{"d":"2023-11-24","n":"Curasight to present at HC Andersen Capital and Stokk.io","u":"/news/press-releases/2023/curasight-to-present-at-hc-andersen-capital-and-stokkio/"},{"d":"2023-12-13","n":"Curasight A/S appoints CRO to run Phase 2 study with uTRACE[®] in prostate cancer","u":"/news/press-releases/2023/curasight-as-appoints-cro-to-run-phase-2-study-with-utrace-in-prostate-cancer/"},{"d":"2023-12-18","n":"Curasight A/S submits clinical trial application (CTA) for phase 2 trial with uTRACE[®] in prostate cancer patients","u":"/news/press-releases/2023/curasight-as-submits-clinical-trial-application-cta-for-phase-2-trial-with-utrace-in-prostate-cancer-patients/"},{"d":"2022-01-18","n":"Curasight presents at the SEB Nordic Healthcare Seminar 2022 and at Kapital Partner","u":"/news/press-releases/2022/curasight-presents-at-the-seb-nordic-healthcare-seminar-2022-and-at-kapital-partner/"},{"d":"2022-01-27","n":"Phase II study of uPAR-PET in neuroendocrine tumor patients demonstrates strong prognostic value and supports potential future use of uPAR-targeted radionuclide therapy","u":"/news/press-releases/2022/phase-ii-study-of-upar-pet-in-neuroendocrine-tumor-patients-demonstrates-strong-prognostic-value-and-supports-potential-future-use-of-upar-targeted-radionuclide-therapy/"},{"d":"2022-02-10","n":"Curasight strengthens its strategic position with the acquisition of TRT Innovations ApS","u":"/news/press-releases/2022/curasight-strengthens-its-strategic-position-with-the-acquisition-of-trt-innovations-aps/"},{"d":"2022-02-23","n":"Curasight expands its strategy and strengthen its position as a theranostic company","u":"/news/press-releases/2022/curasight-expands-its-strategy-and-strengthen-its-position-as-a-theranostic-company/"},{"d":"2022-02-24","n":"Year-end report October - December 2021","u":"/news/press-releases/2022/year-end-report-october---december-2021/"},{"d":"2022-02-24","n":"Annual Report for the fiscal year 2021","u":"/news/press-releases/2022/annual-report-for-the-fiscal-year-2021/"},{"d":"2022-03-09","n":"Curasight announces new date of the Annual General Meeting and an updated financial calendar 2022","u":"/news/press-releases/2022/curasight-announces-new-date-of-the-annual-general-meeting-and-an-updated-financial-calendar-2022/"},{"d":"2022-04-12","n":"Notice of Annual General Meeting 2022","u":"/news/press-releases/2022/notice-
271of-annual-general-meeting-2022/"},{"d":"2022-04-22","n":"Additional US patent application relating to uTRACE[®] is accepted for grant","u":"/news/press-releases/2022/additional-us-patent-application-relating-to-utrace-is-accepted-for-grant/"},{"d":"2022-04-27","n":"Resolutions of the Annual General Meeting of Curasight A/S","u":"/news/press-releases/2022/resolutions-of-the-annual-general-meeting-of-curasight-as/"},{"d":"2022-05-16","n":"Curasight to present at Kapital Partners Life Science seminar","u":"/news/press-releases/2022/curasight-to-present-at-kapital-partners-life-science-seminar/"},{"d":"2022-05-24","n":"Interim Report January - March 2022","u":"/news/press-releases/2022/interim-report-january---march-2022/"},{"d":"2022-06-07","n":"Curasight issues warrants for launch of long-term incentive program","u":"/news/press-releases/2022/curasight-issues-warrants-for-launch-of-long-term-incentive-program/"},{"d":"2022-06-24","n":"Transaction with shares in Curasight A/S made by managerial employee","u":"/news/press-releases/2022/transaction-with-shares-in-curasight-as-made-by-managerial-employee/"},{"d":"2022-06-30","n":"Recruitment completed in uPAR-PET study in brain cancer","u":"/news/press-releases/2022/recruitment-completed-in-upar-pet-study-in-brain-cancer/"},{"d":"2022-08-25","n":"Interim Report January â June 2022","u":"/news/press-releases/2022/interim-report-january--june-2022/"},{"d":"2022-08-25","n":"Curasight to present at HC Andersen Capital","u":"/news/press-releases/2022/curasight-to-present-at-hc-andersen-capital/"},{"d":"2022-09-04","n":"Transaction with shares in Curasight A/S made by managerial employee","u":"/news/press-releases/2022/transaction-with-shares-in-curasight-as-made-by-managerial-employee-2022-09-04/"},{"d":"2022-10-13","n":"Curasight initiates pre-clinical studies with uTREAT[®] therapy in head and neck cancer (HNSCC) and neuroendocrine tumors (NET)","u":"/news/press-releases/2022/curasight-initiates-pre-clinical-studies-with-utreat-therapy-in-head-and-neck-cancer-hnscc-and-neuroendocrine-tumors-net/"},{"d":"2022-11-17","n":"Curasight to present at SEB Healthcare Seminar 2022","u":"/news/press-releases/2022/curasight-to-present-at-seb-healthcare-seminar-2022/"},{"d":"2022-11-23","n":"Curasight to present at HC Andersen Capital","u":"/news/press-releases/2022/curasight-to-present-at-hc-andersen-capital-2022-11-23/"},{"d":"2022-11-24","n":"Interim Report January â September 2022","u":"/news/press-releases/2022/interim-report-january--september-2022/"},{"d":"2021-09-01","n":"Curasight A/S strengthens its institutional investor base","u":"/news/press-releases/2021/curasight-as-strengthens-its-institutional-investor-base/"},{"d":"2021-09-16","n":"The exercise period for warrants of series TO 1 in Curasight A/S begins today","u":"/news/press-releases/2021/the-exercise-period-for-warrants-of-series-to-1-in-curasight-as-begins-today/"},{"d":"2021-09-21","n":"Transactions with warrants of series TO 1 in Curasight A/S made by managerial employees and their closely associated persons","u":"/news/press-releases/2021/transactions-with-warrants-of-series-to-1-in-curasight-as-made-by-managerial-employees-and-their-closely-associated-persons/"},{"d":"2021-09-30","n":"Curasight warrant TO 1 â last day of trading is Tuesday 5 October 2021","u":"/news/press-releases/2021/curasight-warrant-to-1--last-day-of-trading-is-tuesday-5-october-2021/"},{"d":"2021-10-11","n":"Curasight A/S receives approximately DKK 47.6 million through exercise of warrants of series TO 1","u":"/news/press-releases/2021/curasight-as-receives-approximately-dkk-476-million-through-exercise-of-warrants-of-series-to-1/"},{"d":"2021-10-13","n":"Curasight A/S warrant exercise registered at Erhvervsstyrelsen","u":"/news/press-releases/2021/curasight-as-warrant-exercise-registered-at-erhvervsstyrelsen/"},{"d":"2021-10-15","n":"Curasight A/S presents at BioStock Life Science Summit 20 October 2021","u":"/news/press-releases/2021/curasight-as-presents-at-biostock-life-science-summit-20-october-2021/"},{"d":"2021-10-15","n":"Curasight A/S presents at Ãkonomisk Ugebrev Life Science Investor Conference in Copenhagen 20 October 2021","u":"/news/press-releases/2021/curasight-as-presents-at-okonomisk-ugebrev-life-science-investor-conference-in-copenhagen-20-october-2021/"},{"d":"2021-11-23","n":"Curasight presents at HC Andersen Capital","u":"/news/press-releases/2021/curasight-presents-at-hc-andersen-capital-2021-11-23/"},{"d":"2021-11-25","n":"Interim report January â September 2021","u":"/news/press-releases/2021/interim-report-january--september-2021/"},{"d":"2021-12-06","n":"Curasight A/S presents at Sedermeradagen in Copenhagen 7 December 2021","u":"/news/press-releases/2021/curasight-as-presents-at-sedermeradagen-in-copenhagen-7-december-2021/"},{"d":"2021-12-07","n":"Curasight A/S presents at HC Andersen Capital & Nordea Markets Virtual Growth Days seminar - 9 December 2021","u":"/news/press-releases/2021/curasight-as-presents-at-hc-andersen-capital--nordea-markets-virtual-growth-days-seminar---9-december-2021/"},{"d":"2021-12-09","n":"Phase II study demonstrates prognostic value of uPAR-PET in head and neck cancer patients","u":"/news/press-releases/2021/phase-ii-study-demonstrates-prognostic-value-of-upar-pet-in-head-and-neck-cancer-patients/"},{"d":"2021-12-13","n":"Curasight presents at HC Andersen Capital","u":"/news/press-releases/2021/curasight-presents-at-hc-andersen-capital-2021-12-13/"},{"d":"2021-12-14","n":"Transaction with shares in Curasight A/S made by managerial employee","u":"/news/press-releases/2021/transaction-with-shares-in-curasight-as-made-by-managerial-employee/"},{"d":"2021-12-21","n":"Hanne Damgaard Jensen joins Curasight A/S as Chief Development Officer (CDO)","u":"/news/press-releases/2021/hanne-damgaard-jensen-joins-curasight-as-as-chief-development-officer-cdo/"},{"d":"2021-12-30","n":"Curasight attends the J.P. Morgan Healthcare Conference and presents at HC Andersen Capital","u":"/news/press-releases/2021/curasight-attends-the-jp-morgan-healthcare-conference-and-presents-at-hc-andersen-capital/"},{"d":"2021-08-24","n":"Interim report January â June 2021","u":"/news/press-releases/2021/interim-report-january--june-2021/"},{"d":"2021-08-23","n":"Curasight presents at HC Andersen Capital","u":"/news/press-releases/2021/curasight-presents-at-hc-andersen-capital/"},{"d":"2021-02-08","n":"US patent application 14/399,820 relating to uTREAT[®] is accepted for grant","u":"/news/press-releases/2021/us-patent-application-14399820-relating-to-utreat-is-accepted-for-grant/"},{"d":"2021-02-24","n":"Year-end report October â December 2020","u":"/news/press-releases/2021/year-end-report-october--december-2020/"},{"d":"2021-02-24","n":"Annual Report for the fiscal year 2020","u":"/news/press-releases/2021/annual-report-for-the-fiscal-year-2020/"},{"d":"2021-02-26","n":"Article from Phase II study in prostate cancer now published in the March issue of Journ
271al of Nuclear Medicine and highlighted as best clinical investigation article","u":"/news/press-releases/2021/article-from-phase-ii-study-in-prostate-cancer-now-published-in-the-march-issue-of-journal-of-nuclear-medicine-and-highlighted-as-best-clinical-investigation-article/"},{"d":"2021-03-05","n":"Curasight A/S presents at Ãkonomisk Ugebrev Life Science Investor Conference","u":"/news/press-releases/2021/curasight-as-presents-at-okonomisk-ugebrev-life-science-investor-conference/"},{"d":"2021-03-11","n":"Notice of Annual General Meeting","u":"/news/press-releases/2021/notice-of-annual-general-meeting/"},{"d":"2021-03-11","n":"Curasightâs presentation at Ãkonomisk Ugebrev Life Science Investor Conference is now available","u":"/news/press-releases/2021/curasights-presentation-at-okonomisk-ugebrev-life-science-investor-conference-is-now-available/"},{"d":"2021-03-25","n":"Minutes from the Annual General Meeting in Curasight A/S","u":"/news/press-releases/2021/minutes-from-the-annual-general-meeting-in-curasight-as/"},{"d":"2021-03-28","n":"CAD patent application 2,905,172 relating to uTREAT[®] is accepted for grant","u":"/news/press-releases/2021/cad-patent-application-2905172-relating-to-utreat-is-accepted-for-grant/"},{"d":"2021-04-09","n":"Curasight A/S presents at Nordnet Live - Spotlight Small Cap investor conference 15 April 2021","u":"/news/press-releases/2021/curasight-as-presents-at-nordnet-live---spotlight-small-cap-investor-conference-15-april-2021/"},{"d":"2021-05-04","n":"Curasight announces appointment of Dr. Kirsten Drejer as new board member","u":"/news/press-releases/2021/curasight-announces-appointment-of-dr-kirsten-drejer-as-new-board-member/"},{"d":"2021-05-17","n":"Curasight is awarded two prizes in Best IPO 2020 by the independent IPO Guide","u":"/news/press-releases/2021/curasight-is-awarded-two-prizes-in-best-ipo-2020-by-the-independent-ipo-guide/"},{"d":"2021-05-18","n":"Notice of Extraordinary General Meeting","u":"/news/press-releases/2021/notice-of-extraordinary-general-meeting/"},{"d":"2021-05-20","n":"Interim report January â March 2021","u":"/news/press-releases/2021/interim-report-january--march-2021/"},{"d":"2021-05-20","n":"Interim report January â March 2021 â Correction","u":"/news/press-releases/2021/interim-report-january--march-2021--correction/"},{"d":"2021-05-21","n":"Curasight presents at Erik Penser Bank â Temadag Medicinsk Bildteknik & Diagnostik","u":"/news/press-releases/2021/curasight-presents-at-erik-penser-bank--temadag-medicinsk-bildteknik--diagnostik/"},{"d":"2021-05-26","n":"Curasight presents at Bio Stock Life Science Spring Summit","u":"/news/press-releases/2021/curasight-presents-at-bio-stock-life-science-spring-summit/"},{"d":"2021-06-01","n":"Minutes from the Extraordinary General Meeting in Curasight A/S","u":"/news/press-releases/2021/minutes-from-the-extraordinary-general-meeting-in-curasight-as/"},{"d":"2021-06-18","n":"SEB initiates commissioned research on Curasight A/S","u":"/news/press-releases/2021/seb-initiates-commissioned-research-on-curasight-as/"},{"d":"2021-06-24","n":"Positive data of uTREAT® in glioblastoma provides âgreen lightâ to proceed with next steps","u":"/news/press-releases/2021/positive-data-of-utreat-in-glioblastoma-provides-green-light-to-proceed-with-next-steps/"},{"d":"2020-09-03","n":"The subscription period in Curasightâs issue of units starts today","u":"/news/press-releases/2020/the-subscription-period-in-curasights-issue-of-units-starts-today/"},{"d":"2020-09-02","n":"Curasight A/S receives approval for listing and publishes prospectus","u":"/news/press-releases/2020/curasight-as-receives-approval-for-listing-and-publishes-prospectus/"},{"d":"2020-09-09","n":"Webcast with Curasight","u":"/news/press-releases/2020/webcast-with-curasight/"},{"d":"2020-09-22","n":"Significantly oversubscribed IPO of units in Curasight","u":"/news/press-releases/2020/significantly-oversubscribed-ipo-of-units-in-curasight/"},{"d":"2020-10-08","n":"First day of trading in Curasightâs shares and warrants at Spotlight Stock Market","u":"/news/press-releases/202
2710/first-day-of-trading-in-curasights-shares-and-warrants-at-spotlight-stock-market/"},{"d":"2020-10-07","n":"Prolongation and expansion of agreement with TRT Innovations ApS","u":"/news/press-releases/2020/prolongation-and-expansion-of-agreement-with-trt-innovations-aps/"},{"d":"2020-10-22","n":"Canadian patent application relating to uTRACE[®] is ready for allowance in Canada","u":"/news/press-releases/2020/canadian-patent-application-relating-to-utrace-is-ready-for-allowance-in-canada/"},{"d":"2020-11-11","n":"Curasight initiates pre-clinical study on therapy (uTREAT[®]) in brain cancer and signs CRO-agreement","u":"/news/press-releases/2020/curasight-initiates-pre-clinical-study-on-therapy-utreat-in-brain-cancer-and-signs-cro-agreement/"},{"d":"2020-11-30","n":"Interim report January â September 2020","u":"/news/press-releases/2020/interim-report-january--september-2020/"},{"d":"2020-12-15","n":"Financial Calendar 2021","u":"/news/press-releases/2020/financial-calendar-2021/"},{"d":"2020-12-16","n":"Japanese patent application 2019-005811 is accepted for grant","u":"/news/press-releases/2020/japanese-patent-application-2019-005811-is-accepted-for-grant/"},{"d":"2020-12-21","n":"Results from Phase II study in prostate cancer to be published in the Journal of Nuclear Medicine","u":"/news/press-releases/2020/results-from-phase-ii-study-in-prostate-cancer-to-be-published-in-the-journal-of-nuclear-medicine/"},{"d":"2024-02-13","n":"Curasight resolves on a rights issue of up to DKK 51.2 million to accelerate its therapeutic strategy","u":"/investor/archive-financing/rights-issue-2024/curasight-resolves-on-a-rights-issue-of-up-to-dkk-51-2-million-to-accelerate-its-therapeutic-strategy/"},{"d":"2024-02-22","n":"Curasight publishes information memorandum in connection with forthcoming rights issue","u":"/investor/archive-financing/rights-issue-2024/curasight-publishes-information-memorandum-in-connection-with-forthcoming-rights-issue/"},{"d":"2024-02-23","n":"The subscription period in Curasightâs rights issue begins today","u":"/investor/archive-financing/rights-issue-2024/the-subscription-period-in-curasights-rights-issue-begins-today/"}]</div> 272 273 <a class="_download" href="https://publish.ne.cision.com/papi/ShareHistory/47A3AC7342004193B59A2A499F480A54/csv">Download as Excel</a> 274 275</figure> 276 277 </div> 278 279 280 </div> 281 282 </div> 283 </div> 284 285 </div> 286 287 <div data-id="74-4" class="_section-container"> 288 289 <div class="_section"> 290 <div class="_grid"> 291 292 <div id="_74-5" class="_block"> 293 294 295 <div class="_block-content"> 296 297<table class="share-performance"> 298 <caption> 299 <h2>Performance</h2> 300 </caption> 301 <tbody> 302 <tr> 303 <th scope="row">Symbol</th> 304 <td>CURAS</td> 305 </tr> 306 <tr> 307 <th scope="row">Currency</th> 308 <td>DKK </td> 309 </tr> 310 <tr> 311 <th scope="row">Market Place</th> 312 <td>XSAT </td> 313 </tr> 314 <tr> 315 <th scope="row">Latest Price</th> 316 <td><span class="_ticker-price"></span></td> 317 </tr> 318 <tr> 319 <th scope="row">Latest Change</th> 320 <td><span data-tickerformat="D MMM, YYYY" data-when="QuoteTime"></span></td> 321 </tr> 322 <tr> 323 <th scope="row">AT High</th> 324 <td><span data-tickerformat="D MMM, YYYY" data-when="AthDate"></span></td> 325 </tr> 326 <tr> 327 <th scope="row">AT Low</th> 328 <td><span data-tickerformat="D MMM, YYYY" data-when="AtlDate"></span></td> 329 </tr> 330 <tr> 331 <th>Year High</th> 332 <td><span class="_ticker-high1y"></span></td> 333 </tr> 334 <tr> 335 <th>Year Low</th> 336 <td><span class="_ticker-low1y"></span></td> 337 </tr> 338 <tr> 339 <th>NumberofShares</th> 340 <td><span class="_ticker-noofshares"></span></td> 341 </tr> 342 </tbody> 343</table> 344 </div> 345 346 347 </div> 348 349 </div> 350 </div> 351 352 </div> 353 354 <div data-id="74-3" class="_section-container"> 355 356 <div class="_section"> 357 <div class="_grid"> 358 359 <div id="_74-4" class="_block"> 360 361 362 <div class="_block-content"> 363 <h2>Trades</h2><table class="_trades" data-key="7D74DD26506D46E98B94764025870F3C"> 364 <thead> 365 <tr> 366 <th>Price</th> 367 <th>Volume</th> 368 <th>
368Buyer</th> 369 <th>Seller</th> 370 <th>Time</th> 371 </tr> 372 </thead> 373 <tbody></tbody> 374</table> 375 376 </div> 377 378 379 </div> 380 381 </div> 382 </div> 383 384 </div> 385 386 <div data-id="74-5" class="_section-container"> 387 388 <div class="_section"> 389 <div class="_grid"> 390 391 <div id="_74-6" class="_block"> 392 393 394 <div class="_block-content"> 395 <h2>Order book</h2><table class="_orderbook" data-key="1B246F975B8E425FAFD7E55C50C132CC" data-buycolor="#707070" data-sellcolor="#446084 "> 396 <thead> 397 <tr> 398 <th>Buy</th> 399 <th>Volume</th> 400 <th> </th> 401 <th> </th> 402 <th>Volume</th> 403 <th>Sell</th> 404 </tr> 405 </thead> 406 <tbody></tbody> 407</table> 408 409 </div> 410 411 412 </div> 413 414 </div> 415 </div> 416 417 </div> 418 </main></div><footer> 419 <div data-id="11-1" class="_section-container background-mediumgrey space"> 420 421 <div class="_section"> 422 <div class="_grid"> 423 424 <div id="_11-5" class="_block"> 425 426 427 <div class="_block-content"> 428 429<img src="/files/images/curasight-site-logo.png" alt="Curasight" class="footer-logo" /> 430 431 </div> 432 433 434 </div> 435 436 <div id="_11-4" class="_block"> 437 438 439 <div class="_block-content"> 440 <h2>Subscribe</h2><p>Subscribe to get the latest news first.</p> 441 442<form action="//publish.ne.cision.com/Subscription/Subscribe" method="post" class="_subscribe"> 443 <input type="hidden" name="subscriptionUniqueIdentifier" value="3094420cd5"/> 444 <input type="hidden" name="Replylanguage" value="en"/> 445 <div class="_fields"> 446 <div id="9874188198243439"></div> 447 <input style="display: none;" name="Language" type="checkbox" checked value="en"> 448 <h3>Choose type</h3> 449 <div class="types"> 450 451 <label><input name="informationtype" type="checkbox" value="kmk,rpt,rdv"><span>Financial reports</span></label> 452 453 <label><input name="informationtype" type="checkbox" value="prm"><span>Press releases</span></label> 454 455 </div> 456 <label> 457 <span>E-mail</span> 458 <input required type="email" name="Email" placeholder="E-mail"> 459 <div class="_result _fail">Something went wrong - please make sure you entered the correct email.</div> 460 </label> 461 462 <div class="_privacynotice"><p><em data-renderer-mark="true">I consent to Curasight handling my personal data. See Curasight's <a data-testid="link-with-safety" href="/terms-of-use/" title="/terms-of-use/" data-renderer-mark="true" class="css-1rn59kg">Terms of Use</a> for information about how we handle personal data.</em></p></div><button><span>Subscribe</span></button> 463 </div> 464 <div class="_result _success">Thank you. You will get an e-mail message to activate your subscription.</div> 465</form> 466 467 468 </div> 469 470 471 </div> 472 473 <div id="_11-1" class="_block"> 474 475 476 <div class="_block-content"> 477 <p>Curasight is a clinical-stage radiopharmaceutical company advancing uTREAT<sup>®</sup>, a first-in-class uPAR-targeted radioligand therapy (RLT) designed to treat aggressive solid tumors across multiple indications. uTREAT<sup>®</sup> is supported by the clinically validated imaging agent uTRACE<sup>®</sup>, built on the same uPAR-targeting ligand, enabling a differentiated and de-risked theranostic approach.</p> 478<p>uPAR (urokinase-type plasminogen activator receptor) is broadly expressed in aggressive cancers and plays a central role in tumor invasion, angiogenesis, and metastasis. By focusing on this validated and widely expressed target, Curasight is pursuing a therapeutic strategy across multiple high-unmet-need solid tumors using a shared biological target and targeting ligand.</p> 479<p><strong>One target. One therapy. A pipeline-in-a-drug across aggressive solid tumors.</strong></p> 480 </div> 481 482 483 </div> 484 485 </div> 486 </div> 487 488 </div> 489 490 <div data-id="11-2" class="_section-container background-darkgrey"> 491 492 <div class="_section"> 493 <div class="_grid"> 494 495 <div id="_11-3" class="_block"> 496 497 498 <div class="_block-content"> 499 500 501<div class="footer--bottom"> 502 503 <a href="#top" class="back-to-top"> 504 <svg role="img" aria-label="Back to top" width="16" viewB
504ox="0 0 26 26"><use xlink:href="#svg-Nav-hide"></use></svg> 505 </a> 506 507 <ul class="footer__nav"><li><a href="/news/">News and Media</a></li><li><a href="/contact/">Contact</a></li><li><a href="/terms-of-use/">Terms of use</a></li></ul> 508 509 510 <p class="footer__copyright">Copyright 2026 © <strong>Curasight</strong></p> 511 512</div> 513 514 515 516 517 518 519 520 521 522 </div> 523 524 525 </div> 526 527 </div> 528 </div> 529 530 </div> 531 </footer> 532 533<div id="_cookiebanner-opt-in-out" class="hidden _cookiebanner-opt-in-out" data-nosnippet="true"> 534 <div class="_cookiebanner-opt-in-out--inner"> 535 <p>This website uses cookies to provide the best possible user experience. If you continue without making any changes you allow this. 536<a href="/terms-of-use/">Read more about cookies here</a></p> 537 <div class="_cookie-buttons"> 538 <button><span>Accept</span></button> 539 </div> 540 541 542 543 </div> 544 545</div> 546 547 548 549
550<script nonce="/Nix+QO9Op5fAhq+qJNB0Q==">window.waasconfig = {"lang":"en","pageId":74,"template":1,"gaoptout":true,"consentFunctions":[],"initFunctions":[],"cleanupFunctions":[],"optout":true,"plausible":"curasight.com","thousandDelimiter":"","decimalSign":"","youtubedisclaimer":"","youtubeaccept":"","vimeodisclaimer":"","vimeoaccept":"","mapsdisclaimer":"","mapsaccept":""};</script>
550<script src="/main.js?1774614054815"></script>
550 551 552 553
553<script defer src="/api/analytics/"></script>
553 554 555 <div class="overlay-cover"></div> 556 <div class="overlay" aria-hidden="true"> 557 <div class="overlay__outer"> 558 <div class="overlay__inner"> 559 <button class="overlay__close">Close</button> 560 <div class="overlay__content"></div> 561 </div> 562 </div> 563 </div> 564</body> 565</html>
Line numbers count LF bytes from the start of the resource, as the search results do. Vendor segments are library code the classifier recognised; they are stored but not indexed. Bytes are shown as Latin1 characters, one per byte.